After studying Medicine in China, Dr. Zhang pursued PhD study at the Medical University of Ohio, where he studied the role of NF-kB signaling in the control of autoimmunity and lymphomagenesis. Dr. Zhang then had his postdoctoral training with Dr. Klaus Rajewsky and also Dr. Frederick Alt at the Immune Disease Institute and Children’s Hospital Boston, Harvard Medical School, where he focused on understanding the molecular pathogenesis of B-cell lymphomas, and immune surveillance against Epstein-Barr virus (EBV)-associated B-cell lymphomas. Dr. Zhang is now an Assistant Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School. His laboratory continues to research on the molecular basis of lymphoma development, and understand EBV-induced immunity, with the ultimate goal of translating these discoveries into clinical applications. In this regard, his lab is developing and translating a novel immunotherapy for B-cell lymphoma/leukemia.